81. Edgewebhosting.net Focused on the development and commercialization of cancer vaccines and gene therapies to treat various cancers including leukemia, hemophilia A and B, restenosis after angioplasty and Parkinson s disease. http://www.cellgenesys.com/

Hello World This is a site hosted by Edgewebhosting.net Managed Hosting If you are seeing this page in error, please contact us or contact your Client Services Manager directly.

82. Copernicus Therapeutics, Inc. Developing human gene therapy products for cystic fibrosis and hemophilia B and DNA vaccinations. The company creates proprietary PLASmin Complexes which are efficient non-viral vectors and REPLIsome vectors which allow replication of non-viral vectors. http://www.cgsys.com/index/index.asp

Copernicus Therapeutics, Inc. Delivering the promise of nucleic acid therapeutics The last few decades have seen scientists and clinicians rapidly develop an understanding of the basis of many human diseases at the molecular level. Concerted efforts, such as the multi-billion dollar Human Genome Project, have helped provide this information leap. With a better understanding of the molecular basis of many diseases, it has been possible to envision new approaches and drugs to treat previously poorly treated or untreatable diseases. One of the new approaches has been to use the information obtained in the Human Genome itself to develop treatments. Nucleic acids are molecules our bodies use to store and transmit all the information that permits our bodies, organs, tissues and cells to function normally. With the new knowledge obtained and tools developed by scientists, it is now possible for clinician-scientists to devise ways to use nucleic acids as a new class of drugs. There are many ways to use nucleic acids as drugs; some are listed below: It is possible to deliver to cells nucleic acid molecules that serve as a blueprint to make proteins that replace defective proteins. These proteins can be correct copies of defective genes like the CFTR gene that, when mutated, causes cystic fibrosis, the most common monogenetic defect found in Caucasians. This use is called

83. Welcome To GenVec.com! :: GenVec, Inc. An emerging biopharmaceutical company developing novel gene therapies for diseases where local delivery of a therapeutic gene has potential benefits over currently available treatments. New product development initiatives have been formalized for coronary artery disease with BioBypass angiogen, restenosis prevention and cancer. http://www.genvec.com

self.name = 'GenVec'; Contact Us SiteMap Site Search: About GenVec Product Programs Press Releases Investor Relations GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. Each of our product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s TNFerade™ is currently being evaluated for its potential use in the treatment of cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. About GenVec Product Programs Press Releases Investor Relations

84. Transgene - Immunotherapy To Fight Cancer And Infectious Diseases Gene therapy company based in France is developing products for cancer and cystic fibrosis. Vector platforms include adenovirus, retrovirus, vaccinia virus, cellular and synthetic vectors. http://www.transgene.fr/us/

85. VirRx Cancer Gene Therapy Website A biotechnology company with a primary interest in cancer gene therapy. http://www.virrx.com

Harnessing viruses to treat cancer Who We Are Lay Description Scientific Description

86. Novasep | Life Sciences Manufacturing Solutions A GMP biomanufacturing company located in Belgium, able to produce, purify and aseptically fill clinical batches of therapeutic proteins, monoclonal antibodies, plasmid DNA, vaccinal viruses or viral vectors for gene therapy. http://www.henogen.com/

87. ACGT® - Alliance For Cancer Gene Therapy - National Grants For Cancer Research Raises and distributes funds for scientific research into the causes, treatment and prevention of all types of cancer, utilizing cells and genes as medicines. http://www.acgtfoundation.org

About ACGT Founder's Message Why ACGT is Unique National Reach ... TREATMENT ACGT is in the right place at the right time, leading the way for innovative research using cells and genes as "medicine." Everyday, research progresses successfully from the laboratory to clinical translation, moving closer to a less debilitating, more effective treatment approach essential to the quality of life and survival of cancer patients. ACGT is approved by the coalition of the Better Business Bureau and the National Charities Information Bureau for meeting the highest standards of governance, effectiveness, public communications and financial responsibility. Send this page to a friend Follow us... ACGT's September 2010 eNews ACGT's June 2010 Newsletter Greenwich Post's Article about the Swim Across America Event Cell Therapy Vaccine Approved for Prostate Cancer ... Site Contents ACGT is a 501(c)(3) organization and all contributions are tax-deductible.

88. Home Page For The Website Of The British Society For Gene Therapy (BSGT) UK society that aims to accelerate scientific progress and promote ethical and thorough transfer of gene- and cell-based technologies from the laboratory into the clinic. http://www.bsgt.org

89. NGVL: National Gene Vector Laboratories An interactive group of academic production and pharmacology/toxicology laboratories whose primary goal is to provide eligible investigators with clinical grade vectors for phase I/II gene therapy clinical trials and to provide support for relevant pharmacology/toxicology studies leading up to clinical gene transfer protocols. http://www.ngvl.org

NGVB Home Toxicology Database SeqMap Database ... Contacts Log in to site username: password: The National Gene Vector Laboratories (NGVL) was a gene therapy manufacturing and toxicology resource previously sponsored by the National Center for Research Resources, NIH. The program has been discontinued and is no longer offering manufacturing or toxicology services. While vector production and toxicology studies are no longer supported, the NCRR has created a new program to assist gene therapy investigators, the National Gene Vector Biorepository ( www.ngvbcc.org ). The NGVB maintains a number of resources previously associated with the NGVL, including the NGVL Pharmacology/Toxicology Database and SeqMap bioinformatics tool for insertion site analysis. The NGVB now offers a variety of archiving services, educational resources, and a reagent repository. The NGVB Coordinating Center is located in the Department of Medical and Molecular Genetics at the Indiana University School of Medicine, the same site as the previous NGVL Coordinating Center. If you have previously obtained NGVL support and have questions or concerns, please contact Lorraine Matheson lrubin at iupui dot edu or visit the NGVB website ( www.ngvbcc.org

90. Oxford University GeneMedicine Research Group Focused on the development gene therapies for diseases of the airway, such as asthma, lung cancer and in particular, cystic fibrosis (CF). Work includes formulation development, reagent production, pre-clinical testing, and human clinical trials. http://users.ox.ac.uk/~genemed/default.htm

91. Duchenne Muscular Dystrophy - Jesse's Journey - The Foundation For Gene And Cell A registered charitable organization raising funds for research in gene and cell based therapies focusing on Duchenne muscular dystrophy and other neuromuscular diseases. http://www.jessesjourney.com

92. Office Of Biotechnology Activities At The NIH Monitors scientific progress and ethical issues in basic and clinical research involving recombinant DNA and human gene transfer at NIH funded institutions. http://www4.od.nih.gov/oba/

93. Centre For Gene Therapeutics, Gene Transfer Technology, Genomics, Target Gene Pr The mission of the Centre is to investigate, create and implement approaches utilizing the delivery of genes as therapeutic agents in the treatment of human and animal disease. http://www.fhs.mcmaster.ca/cgt/

MUGSI Quick Links Select A to Z Campus Index Alumni Association Bookstore Campus Health Centre Career Services Clubs Employers Financial Aid Find People @ McMaster Giving to McMaster Housing International Students Libraries Media MUGSI Login Policies Security Services Student Accounts Work/Study Abroad Working@McMaster Search McMaster FHS CGT McMaster McMaster A-Z Index Faculty of Health Sciences Department of Pathology Faculty of Health Sciences Centre for Gene Therapeutics CGT Home Director's Welcome Research Funding ... Contact Us CGT on Facebook initializeNavTree("submenu"); Larger Text Smaller Text Print Centre for Gene Therapeutics The Centre is focused on developing novel cures for cancer, inflammatory diseases and infectious diseases. Working as a team, our scientists and clinicians have developed a world-class institute boasting cutting-edge research facilities and provide the most up-to-date medical solutions for the people of Southern Ontario and Canada. Events Recent Selected Publications updated July 2010 Special Seminar Announcements updated July 2010 Work-in-Progress Seminar Series 2009/2010 schedule updated October 2010 2009/2010 schedule updated October 2010 Journal Club 2010 Schedule The CGT Journal club will be holding its first meeting of the 2010-2011 academic year on September 17th at 1:00 in MDCL 4023. Please forward any papers for consideration to Cale Zavitz at

94. Royal Holloway, University Of London : School Of Biological Sciences Research in novel gene therapeutics for the treatment of the muscular dystrophies, atherosclerosis, hyperlipidaemia, Parkinson and Altzheimer disease. http://www.rhul.ac.uk/Biological-Sciences/AcademicStaff/Dickson/index.html

/* overLIB (c) Erik Bosrup */ /* overLIB enhancements (c) Philip TAYLOR */ /* MM enhancements (c) Philip TAYLOR */ DD.enabled = true School of Biological Sciences About Us Research Prospective Students ... Staff School of Biological Sciences Teaching Other links South West London Academic Network (SWAN) British Society for Gene Therapy George Dickson, Professor of Molecular Biology, Director SWAN, IBLIS School of Biological Sciences Royal Holloway University of London Egham, Surrey, TW20 0EX United Kingdom Tel: 01784-443545 (01784-276326, Secretary) Fax: 01784-414224 E-mail: g.dickson@rhul.ac.uk Research Molecular Genetics and Gene Therapy of Neuromuscular, Cardiovascular and Neurodegenerative Diseases NEXT Back to TOP Keywords: Muscular dystrophy; dystrophin; gene therapy; antisense therapy; RNAi therapy exon skipping; atherosclerosis; neurodegenerative disease; OPMD; DMD; repeat-expansion disease; HIV/ AIDS; vaccines; adenoviral vector; retroviral vector; adeno-associated virus vector; non-viral vectors; apolipoprotein E; apolipoprotein AI; LCAT; PABPN1; dystroglycan; skeletal muscle; utrophin We are involved in studying the molecular biology and molecular pathology of the nervous, cardiovascular, and skeleto-muscular systems. The programme involves development of gene therapeutics (lentiviral, adenoviral, adeno-associated virus, non-viral lipoplex vectors, oligonucleotide-based pharmaceuticals), use of transgenic animals and the understanding of signalling pathways in relation to the pathophysiology and treatment of the muscular dystrophies, atherosclerosis and hyperlipidaemia, and neurodegenerative disease. The work is supported by the European Union, Medical Research Council, Wellcome Trust, Muscular Dystrophy Campaign, British Heart Foundation, Wyeth Discovery, Gates Foundation, Glaxo-SmithKline, Association Francais contre les Myopathies, Muscular Dystrophy Association.

95. Chamberlain Laboratory, UW Department Of Neurology Main focus of research is the development of gene and cell therapies that can correct and treat the muscular dystrophies. http://depts.washington.edu/chamblab/

University of Washington Department of Neurology about us Dr. Jeffrey Chamberlain is the principal investigator of the Chamberlain Lab in the Department of Neurology, University of Washington School of Medicine and director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center. The main focus of our research is on the muscular dystrophies, primarily Duchenne muscular dystrophy (DMD), with two major goals: to develop a better understanding of the molecular basis of the pathophysiology of the diseases, and to develop gene and cell therapies that will correct and treat the muscular dystrophies. DMD is the most common form of muscular dystrophy, affecting one in 3,500 newborn males, and is caused by mutations in the dystrophin gene. Currently, the laboratory includes ~20 scientists conducting cutting edge studies that we hope to translate into clinical trials in the near future. We are working with some of the best doctors and scientists at Children's Hospital, Fred Hutchinson Cancer Research Center, the VA Hospital, and Harborview Medical Center to most effectively tackle the challenge ahead: to find a treatment for muscular dystrophy. recent news Dr. Chamberlain's book

96. A. I. Virtanen Institute For Molecular Sciences Activities in this institute focus on the development of gene and protein-based approaches for the treatment of cardiovascular diseases and malignant glioma. http://www.uku.fi/aivi/btmm/

Department Research Groups Animal Biotechnology Gene Transfer Technology ... Novel Target Molecules The Department of Biotechnology and Molecular Medicine focuses especially on gene therapy and gene transfer technology, and on animal biotechnology. Director of the Department is Professor Ari Hinkkanen and Vice Director is Professor The Department houses five (5) research groups: Animal Biotechnology , led by Professor Leena Alhonen Gene Transfer Technology, led by Professor Ari Hinkkanen Molecular Physiology, led by Research Director Pasi Tavi Molecular Medicine , led by Professor Novel Target Molecules, led by Professor Pirjo Laakkonen The Department is responsible for the following core facilities of the Institute: Embryo laboratories for the production of transgenic and gene-disrupted animals Automated DNA sequencing unit Adeno, retro, and lentivirus laboratories for gene therapy vectors; biosafety level 2 GMPlaboratory; biosafety level 3 A. I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, P.O. Box 1627, FI-70211 Kuopio, FINLAND; Visiting address: Neulaniementie 2;

97. Eleanor Roosevelt Institute Conducts basic biomedical research into therapies for Down Syndrome, ALS, cancer, and Rec8 Syndrome. Includes map of chromosone 21, employment details and links to related resources. http://www.eri.du.edu/

98. Molecular Therapy - Elsevier Publishes original scientific papers in the areas of gene transfer, gene regulation, gene discovery, cell therapy, experimental models, correction of genetic and acquired diseases, and clinical trials. http://www.elsevier.com/wps/find/journaldescription.cws_home/622922/description#

99. Biologics | Recipharm Contract manufacturing organisation focusing on the production of protein, viral and DNA-based therapeutics at cGMP grade. http://www.cobrabio.com/

100. Nature Technology Corporation Genetic technology and services company, focusing on plasmid DNA manufacturing, DNA vaccines and genetic vectors. http://www.natx.com/

VECTORS X X CELL LINES X X DNA VACCINES X X PRECISION CLONING X X PROTEINS X X PLASMIDS X X PROCESS DEVELOPMENT X X DNA FERMENTATION PROCESS X X HYPERTAQ™ Nature Technology Corporation is a discovery-based bioengineering technology company, providing industry solutions for biopharmaceutical development: vectors; strains; processes; and products; including manufacturing and technology transfer. NTC specializes in services for manufacturing recombinant plasmids (gene therapeutics and DNA vaccines) and proteins. Learn more about our Full Cirlce Biopharmacuetical Development..... Rational design and advanced molecular technology (Gene Self Assembly, GENSA) has led to highly effective viral and non-viral vectors, designer proteins, gene therapeutics and DNA vaccines. Advanced strain engineering technology (Genome Mass Transfer, GMT) allows specialty microbial genomes to be created from existing host strains, incorporating the genetic and regulatory elements for highest-yield production and simplified processing. Process development creates and integrates essential engineering components of upstream (fermentation) and downstream (purification) technologies, resulting in highest-purity and greatest-yield products. Tech transfer completes the cycle by integrating production technologies into client or CMO facilities for quality manufacturing of safe and effective biologics. NTC offers highly purified custom plasmid DNA manufacturing and recombinant protein production services.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 100    Back | 1  | 2  | 3  | 4  | 5